BR112013017953A2 - Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora - Google Patents

Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora

Info

Publication number
BR112013017953A2
BR112013017953A2 BR112013017953A BR112013017953A BR112013017953A2 BR 112013017953 A2 BR112013017953 A2 BR 112013017953A2 BR 112013017953 A BR112013017953 A BR 112013017953A BR 112013017953 A BR112013017953 A BR 112013017953A BR 112013017953 A2 BR112013017953 A2 BR 112013017953A2
Authority
BR
Brazil
Prior art keywords
composition
photosensitizing
topical formulation
pharmaceutical composition
pharmaceutical
Prior art date
Application number
BR112013017953A
Other languages
English (en)
Inventor
A Morris Jerome
Utkhede Deepank
W C Hunt David
Original Assignee
Quadra Logic Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadra Logic Tech Inc filed Critical Quadra Logic Tech Inc
Publication of BR112013017953A2 publication Critical patent/BR112013017953A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIÇÃO FARMACÊUTICA, FORMULAÇÃO TÓPICA, MÉTODO, E, COMPOSIÇÃO FOTOSSENSIBILIZADORA. A invenção inclui e fornece composições que compreendem agentes fotossensibilizadores e seu uso em terapia fotodinâmica para o tratamento de condilções dermatológicas.
BR112013017953A 2011-01-13 2012-01-13 Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora BR112013017953A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161432453P 2011-01-13 2011-01-13
PCT/US2012/021263 WO2012097264A2 (en) 2011-01-13 2012-01-13 Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof

Publications (1)

Publication Number Publication Date
BR112013017953A2 true BR112013017953A2 (pt) 2017-08-29

Family

ID=45563542

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013017953A BR112013017953A2 (pt) 2011-01-13 2012-01-13 Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora

Country Status (10)

Country Link
US (1) US20130289089A1 (pt)
EP (1) EP2663285A2 (pt)
JP (1) JP5964322B2 (pt)
KR (1) KR20140089478A (pt)
CN (1) CN103607999A (pt)
AU (1) AU2012205410A1 (pt)
BR (1) BR112013017953A2 (pt)
CA (1) CA2824768A1 (pt)
MX (1) MX2013008175A (pt)
WO (1) WO2012097264A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2641906B1 (en) 2009-07-08 2015-04-22 Dermira (Canada), Inc. Tofa analogs useful in treating dermatological disorders or conditions
MX2015000429A (es) * 2012-07-11 2015-07-14 Dermira Inc Composiciones farmaceuticas para el suministro topico de fotosesibilizadores y usos de los mismos.
US10118352B2 (en) * 2013-05-31 2018-11-06 LM WP Patent Holdings A/S System and method for assisting in the manufacture of a wind turbine blade shell
EP3851161A1 (en) 2015-10-15 2021-07-21 DUSA Pharmaceuticals, Inc. Adjustable illuminator for photodynamic therapy and diagnosis
US10603508B2 (en) 2015-10-15 2020-03-31 Dusa Pharmaceuticals, Inc. Adjustable illuminators and methods for photodynamic therapy and diagnosis
CA3053507A1 (en) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Compositions for treating acne
WO2018148795A1 (en) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Compositions for treating acne
WO2019018408A1 (en) * 2017-07-17 2019-01-24 Andrea Willey METHOD OF PHOTODYNAMIC THERAPY AGAINST SKIN DISORDERS
US10357567B1 (en) 2018-01-12 2019-07-23 Dusa Pharmaceuticals, Inc. Methods for photodynamic therapy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0774145B2 (ja) * 1986-12-15 1995-08-09 株式会社資生堂 結晶性薬物含有乳化組成物
US4920143A (en) 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5283255A (en) 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US4883790A (en) 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5095030A (en) 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
GB8805849D0 (en) 1988-03-11 1988-04-13 Efamol Holdings Porphyrins & cancer treatment
GB9207988D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Topical composition
GB9513572D0 (en) 1995-07-04 1995-09-06 Ag Patents Ltd Infusion container
US5880145A (en) 1997-05-07 1999-03-09 The University Of British Columbia Class of benzoporphyrin derivative photoactive compounds
IL132494A0 (en) 1997-05-07 2001-03-19 Univ British Columbia A new class of benzoporphyrin derivative photoactive compounds
KR100397131B1 (ko) 1997-05-07 2003-09-13 유니버시티 오브 브리티시 콜롬비아 광활성제로서 모노하이드로벤조포르피린 유도체의 에틸렌글리콜 에스테르
US5954703A (en) * 1997-10-31 1999-09-21 Dusa Pharmaceuticals, Inc. Method and apparatus for applying 5-aminolevulinic acid
US6004821A (en) 1998-03-07 1999-12-21 Levine; Robert A. Method and apparatus for performing chemical, qualitative, quantitative, and semi-quantitative analyses of a urine sample
US6223071B1 (en) 1998-05-01 2001-04-24 Dusa Pharmaceuticals Inc. Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light
SE9801705D0 (sv) * 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
US6887260B1 (en) * 1998-11-30 2005-05-03 Light Bioscience, Llc Method and apparatus for acne treatment
MY138222A (en) 1999-07-19 2009-05-29 Thomson Licensing Sa Tuning system for achieving rapid signal acquisition for a digital satellite receiver
IL133253A0 (en) 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
ATE463237T1 (de) * 2000-08-16 2010-04-15 Gen Hospital Corp Topische aminolevulinsäure-photodynamische therapie für akne vulgaris
JP2005514346A (ja) * 2001-11-09 2005-05-19 キュー エル ティー インク． 光感作剤及び皮膚浸透エンハンサーを含有する組成物並びに光力学療法におけるそれらの使用
US20040073277A1 (en) * 2002-04-05 2004-04-15 Geronemus Roy G. High fluence rate activation of photosensitizers for dermatological applications
WO2005120572A1 (en) * 2004-06-09 2005-12-22 Qlt Inc. Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders using topically applied hydrophobic green porphyrins
CA2457214A1 (en) * 2004-02-06 2005-08-06 Qlt Inc. Photodynamic therapy for the treatment of acne

Also Published As

Publication number Publication date
JP2014505693A (ja) 2014-03-06
JP5964322B2 (ja) 2016-08-03
AU2012205410A1 (en) 2013-08-01
WO2012097264A2 (en) 2012-07-19
MX2013008175A (es) 2013-12-16
CN103607999A (zh) 2014-02-26
WO2012097264A3 (en) 2012-10-18
NZ613168A (en) 2015-06-26
CA2824768A1 (en) 2012-07-19
KR20140089478A (ko) 2014-07-15
EP2663285A2 (en) 2013-11-20
US20130289089A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
BR112013017953A2 (pt) Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112018001640A2 (pt) combinação de antagonista da pd-1 com um inibidor de egfr
GT201300320A (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer.
BR112014016805A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
ECSP12012310A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
PE20180399A1 (es) Composiciones transdermicas de ibuprofeno y metodos de uso de las mismas
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BR112012022243A8 (pt) Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
AR087790A1 (es) Uso de un inhibidor de aromatasa para el tratamiento de hipogonadismo y enfermedades relacionadas
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
BR112014027047A2 (pt) nova formulação
UY33790A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k e inhibidor de mek.
BR112012014159A2 (pt) Combinações terapêuticas de teobromina e um anti-histamínico

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]